NetworkNewsBreaks Archive - Page 1064 of 1733

ThursdayMar 05, 2020 12:16 pm

NetworkNewsBreaks – Vectrus Inc. (NYSE: VEC) Featured in Noble Capital Markets Research Update

Vectrus Inc. (NYSE: VEC) was featured in a recent equity research update published by Noble Capital Markets. The report reads, “Strong 4Q19 and FY2019. 4Q19 revenue grew 11% to $365.3 million, adjusted EBITDA rose 29% to $18 million and adjusted diluted EPS was $0.93 compared to $0.73 in 4Q18. Full year revenue was up 8% to $1.38 billion, adjusted EBITDA rose 15% to $61.4 million, and adjusted diluted EPS was $3.21 compared to $3.04 in 2018.” To view the update and gain access to the full report, visit http://nnw.fm/k0POY About Vectrus Inc. Vectrus is a leading provider of global service solutions with…

ThursdayMar 05, 2020 12:09 pm

NetworkNewsBreaks – MCTC Holdings, Inc. (MCTC) Enters Sales and Distribution Agreement with Sinister CBD LLC for Hemp You Can Feel(TM) Coffee Product Line

MCTC Holdings (OTC: MCTC), a cannabinoid and hemp extract science forward company developing infusion and delivery technologies, today announced its receipt of an initial order from Sinister CBD, LLC for sales and distribution of its Hemp You Can Feel(TM) Coffee product line. Hemp You Can Feel(TM), MCTC’s new product line based on its patent-pending infusion technologies, is the industry's first 100% natural hemp extract and CBD coffee to be shipped in 100% compostable single-serving coffee pods. Under the agreement, MCTC will private label its coffee products under the Sinister CBD brand name and other brands to be included in subsequent…

ThursdayMar 05, 2020 12:01 pm

NetworkNewsBreaks – aTyr Pharma Inc. (NASDAQ: LIFE) Featured in ROTH Equity Research Report

aTyr Pharma Inc. (NASDAQ: LIFE) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “We are initiating coverage of aTyr with a Buy rating and $15 PT. Our investment thesis is based on 1) strong scientific data for aTYR’s lead candidate, ATYR1923, a tRNA synthetase-derived drug for Pulmonary Sarcoidosis an interstitial lung disease (ILD) for which efficacy data is expected during 3Q20, 2) '1923's potential to capture share in the larger ILD market, and 3) collaborations with CSL-Behring (CSLLY-NC) and Kyorin (4569:TYO-NC) that provide further platform validation and non-dilutive capital.” To request…

ThursdayMar 05, 2020 11:54 am

NetworkNewsBreaks – Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) Featured in Mizuho Securities Research Report

Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We are including IQVIA scripts for Gvoke and glucagon below for the week ended 2/21/2020. Gvoke TRx was +24.6% to 294 from 236 the prior week; Gvoke NRx was +26.8% to 284 from 224 the prior week. Total Glucagon TRx was 12,004, +14.0% y/y; total Glucagon NRx was +14.1% y/y to 9,509.” To request access to the full report, visit http://nnw.fm/SaZ9d About Xeris Pharmaceuticals, Inc. Xeris is a specialty pharmaceutical company delivering innovative solutions to simplify the experience…

ThursdayMar 05, 2020 11:47 am

NetworkNewsBreaks – Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) Featured in Mizuho Securities Research Report

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Concert reported 4Q19/FY19 results yesterday. 4Q19 EPS was $(0.86) compared to FactSet consensus of $(0.79) while FY19 EPS was $(3.29) vs. consensus of $(3.22). We do not see earnings as the most important value driver for pre-commercial stage biotechs. Importantly, the company continues to make progress on the clinical development front with CTP-543, and CTP-692 - two wholly-owned assets. We continue to expect that the Phase 2 readouts from CTP-692 in schizophrenia expected by YE2020 could be an…

ThursdayMar 05, 2020 11:39 am

NetworkNewsBreaks – Forty Seven, Inc. (NASDAQ: FTSV) Featured in Mizuho Securities Research Report

Forty Seven, Inc. (NASDAQ: FTSV) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “GILD to acquire FTSV in an all cash deal for $95.50 per share, valuing FTSV at ~$4.9 bln. The deal is expected to close 2Q20, and is subject to regulatory approvals and other customary closing conditions. We have previously written about the possibility of an acquisition or partnership in a previous note.” To request access to the full report, visit http://nnw.fm/SaZ9d About Forty Seven, Inc. Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer…

ThursdayMar 05, 2020 11:26 am

NetworkNewsBreaks – Zogenix, Inc. (NASDAQ: ZGNX) Featured in Mizuho Securities Research Report

Zogenix, Inc. (NASDAQ: ZGNX) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Zogenix reported earnings yesterday. 4Q19 EPS was $(1.26) vs. FactSet consensus of $(1.04) and FY19 EPS was $(9.74) vs. consensus of $(9.54). We do not see earnings as the most important value driver for ZGNX at this stage. Importantly, we remain confident in the potential FDA approval of FINTEPLA for the treatment of Dravet syndrome (PDUFA: 06/25/20). On yesterday's call, management highlighted two-year interim data showing long-term reductions in seizure frequency, supporting our view that FINTEPLA may be differentiated…

ThursdayMar 05, 2020 11:18 am

NetworkNewsBreaks – Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) Featured in Mizuho Securities Research Report

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We get our weekly data from IQVIA, which uses a statistical methodology that requires the extrapolation of data from pharmacies that respond to weekly surveys. During a product launch, volumes can be lumpy across pharmacies which we believe makes it more difficult to extrapolate data. As such, we note that AERI publishes sales-out data on their website monthly (see here for most recent, slide 8), which provides a more complete picture of their weekly sales data.” To request…

ThursdayMar 05, 2020 11:15 am

NetworkNewsBreaks – Trxade Group, Inc. (NASDAQ: MEDS) to Exhibit at HIMSS 2020 Global Health Conference & Exhibition

Trxade Group (NASDAQ: MEDS), an integrated drug procurement, delivery and healthcare platform that enables drug availability, care services and price transparency for both pharmacists and consumers, today announced that it will exhibit at HIMSS 2020. The event, which will draw over 45,000 healthcare professionals, is slated to take place at the Orange County Convention center in Orlando, Florida from March 9-13. Trxade’s booth will be located in Exhibit Hall E, Booth (#7273), Kiosk (#13). Members from the company’s leadership team will be present and provide detailed DEMO and information on products including: DelivMeds and Bonum Health, demonstrating the latest advances…

ThursdayMar 05, 2020 11:10 am

NetworkNewsBreaks – Genprex, Inc.’s (NASDAQ: GNPX) Lead Researcher Behind its Diabetes Gene Therapy Featured in New Video Interview

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing treatments for cancer and other serious diseases, today announced that Dr. George Gittes, the lead researcher and Harvard graduate that developed Genprex’s new potentially curative diabetes gene therapy, was featured in a video interview discussing the therapy. According to the update, Dr. Gittes joined one of Proactive’s broadcast journalists to provide an overview of the gene therapy, how it works, how it may have the potential to help treat type 1 and type 2 diabetes, as well as next steps to move the gene therapy to the clinic. “We…

Financial news and publishing for public and private companies

Contact us: 212.418.1217

NetworkNewsBreaks